At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 11 enrolled
Drug / intervention
Ketoconazole 2% Foamdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Ketoconazole Foam 2% for the Treatment of Versicolor
In Brief
A Phase 4 clinical trial evaluating Ketoconazole 2% Foam for Tinea Versicolor. Completed, enrolled 11 participants across 1 site.
Detailed Summary
Ten adult patients age 19 and older with a clinical diagnosis of tinea versicolor, as well as a positive Potassium Hydroxide (KOH) using calcofluor. Ketoconazole 2% foam will be used to determine its effectiveness, safety and satisfaction when used to treat tinea versicolor.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTinea Versicolor
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartNov 2008
First PostedJan 2009
Primary CompletionAug 2010
Study CompletionSep 2010
TodayJul 2026
First PostedJan 27, 2009
Enrollment StartNov 1, 2008
Primary CompletionAug 1, 2010
Study CompletionSep 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 17.4 years ago
Interventions
Ketoconazole 2% Foamdrug
Ketoconazole 2% Foam, twice daily application to affected areas for 4 weeks.